Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 72,75 € (+2,83 %). Medianen er 83,46 € (+17,96 %).

Køb	11
Behold	3
Sælg	0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

Nyheder Til nyhedsfeedet

CareDx focuses on post-transplant monitoring and predictable revenues

CareDx is a US specialist in molecular diagnostic tests and digital software solutions for monitoring patients before and after organ transplants. The business model is based on non-invasive blood tests for early detection of organ rejection and integrated software for transplant centers, creating predictable and recurring revenue. After a period of regulatory challenges, CareDx has realigned to promote growth and stability. » Mere på finanzen.net
Caredx reaches 52-week high at $53.71

Caredx shares rose to a 52-week high of $53.71 and are currently trading at $53.54 (market capitalization $2.74 billion). Year-to-date performance is 275.74%, the Piotroski score is 9 and the PEG ratio is 0.22. In Q2 2026 Caredx beat estimates with adjusted EPS of $0.37 and revenue of $132 million and raised its full-year guidance. Canaccord Genuity initiated coverage with a buy rating and $65 price target; H.C. Wainwright maintained neutral with a $46 price target; an InvestingPro analysis currently sees the stock trading above its fair value. » Mere på de.investing.com
Caredx hits 52-week high at $49.77 and raises full-year guidance

Caredx shares climbed to a 52-week high of $49.77 (current price $49.69) and show a year-to-date gain of 283.22%. InvestingPro considers the stock overvalued despite a market capitalization of $2.57 billion, but assigns a Piotroski score of 9 and a PEG of 0.2. In Q2 Caredx beat expectations with adjusted EPS of $0.37 (expectation $0.23) and revenue of about $132 million, driven by testing revenue of $99.9 million (+61% y/y). The company raised its full-year guidance; H.C. Wainwright maintains a “Neutral” rating with a $46 price target. » Mere på de.investing.com
Baron Discovery Fund boosts position in CareDx after buying low during CMS LCD uncertainty

Baron Discovery Fund said CareDx contributed positively to Q2 2026 performance after the fund increased its stake when shares traded near $11–$12 amid CMS MolDX draft LCD concerns. CareDx reported strong Q1 results with revenue up 39% y/y and testing volumes up 17% y/y, and completed deals to divest its lab products business and acquire Naveris to enter head and neck cancer testing. Shares have rebounded sharply, trading at $47.23 on Aug. 11 with a YTD gain of about 151% and strong one‑month and one‑year returns. » Mere på finance.yahoo.com
CareDx grows 52% in second quarter and enters oncology with acquisition of Naveris

CareDx reports a revenue increase of more than 52% in Q2 and continues to focus on precision medicine for transplant-related monitoring tests. The acquisition of Naveris for up to $260 million marks the company’s strategic entry into oncology. An upcoming CMS decision on reimbursements could further boost demand for the tests. » Mere på finanzen.net

Virksomhedstal

I det seneste kvartal havde CareDx en omsætning på 123,04 mio. € og et nettoresultat på 17,03 mio. €

(EUR)	september 2026	YoY
Omsætning	123,04 mio.	44,31 %
Bruttofortjeneste	87,47 mio.	47,90 %
Nettoresultat	17,03 mio.	1.093,28 %
EBITDA	15,8 mio.	277,08 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	3,8 mia. €
Antal aktier	52,54 mio.
Højeste/laveste i 52 uger	82,43 € - 13,74 €
Udbytte	Nej
Beta	2,49
P/E (PE Ratio)	32,05
PEG (PEG Ratio)	-0,03
K/I (PB Ratio)	8,90
P/S (PS Ratio)	8,43

Virksomhedsprofil

CareDx, Inc. udvikler, udvikler og kommercialiserer diagnostiske løsninger til transplantationspatienter og deres plejere over hele verden. Virksomheden leverer AlloSure Kidney, en donor-afledt cellefri DNA (dd-cfDNA)-løsning til nyretransplantationspatienter; AlloMap Heart, en genekspressionsløsning til hjertetransplantationspatienter; AlloSure Heart, en dd-cfDNA-løsning til hjertetransplantationspatienter; og AlloSure Lung, en dd-cfDNA-løsning til lungetransplantationspatienter. Virksomheden tilbyder desuden TruSight HLA, en højopløselig typebestemmelsesløsning baseret på næste generations sekventering (NGS); Olerup SSP, som anvendes til typebestemmelse af humane leukocytantigen (HLA)-alleler baseret på sekvensspecifik primerteknologi; QTYPE, som muliggør præcision i HLA-typebestemmelse; samt Ottr, en software til styring af transplantationspatienter. Derudover leverer virksomheden AlloSeq Tx, en højopløselig HLA-typebestemmelsesløsning; AlloSeq cfDNA, en overvågningsløsning til måling af dd-cfDNA i blod; AlloSeq HCT, en løsning til kimærismetest for modtagere af stamcelletransplantationer; og XynQAPI, løsninger til sporing af transplantationskvalitet og styring af venteliste, samt AlloCare, en mobilapp, der tilbyder en patientcentreret ressource for transplantationsmodtagere. Virksomheden tilbyder sine produkter direkte til kunder samt gennem tredjepartsdistributører og underdistributører. Den har en licensaftale med Illumina, Inc. om distribution, udvikling og kommercialisering af NGS-produkter og -teknologier; og med Cibiltech SAS om kommercialisering af iBox, en software til forudsigende analyse af tab af nyreallograft efter transplantation. Virksomheden var tidligere kendt som XDx, Inc. og skiftede navn til CareDx, Inc. i marts 2014. Virksomheden blev stiftet i 1998 og har hovedkontor i South San Francisco, Californien.